{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:34:39Z","timestamp":1784010879450,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007113","name":"Arak University of Medical Sciences","doi-asserted-by":"publisher","award":["1719"],"award-info":[{"award-number":["1719"]}],"id":[{"id":"10.13039\/501100007113","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.htct.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T16:45:50Z","timestamp":1648572350000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-0094","authenticated-orcid":false,"given":"Aziz","family":"Eghbali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-7117","authenticated-orcid":false,"given":"Fatemeh Khazaei","family":"Kohpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-3123","authenticated-orcid":false,"given":"Kazem","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-8798","authenticated-orcid":false,"given":"Roghayeh Rahimi","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-2270","authenticated-orcid":false,"given":"Aygin","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4996-7656","authenticated-orcid":false,"given":"Ali","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.htct.2022.02.004_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13020-020-00333-x","article-title":"Efficacy of acupuncture in the prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: a multi-center, single-blind, randomized, sham-controlled clinical research","volume":"15","author":"Li","year":"2020","journal-title":"Chinese Med"},{"issue":"4","key":"10.1016\/j.htct.2022.02.004_bib0002","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/01635581.2018.1527375","article-title":"Randomized study of the effect of dietary counseling during adjuvant chemotherapy on chemotherapy induced nausea and vomiting, and quality of life in patients with breast cancer","volume":"71","author":"Najafi","year":"2019","journal-title":"Nutr Cancer"},{"issue":"10","key":"10.1016\/j.htct.2022.02.004_bib0003","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b21-00198","article-title":"Palonosetron versus granisetron in combination with aprepitant and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy: a single-institutional retrospective Cohort Study","volume":"44","author":"Miyoshi","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.htct.2022.02.004_bib0004","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"10","key":"10.1016\/j.htct.2022.02.004_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0840-0","article-title":"Latest update on prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"21","author":"Sherani","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.htct.2022.02.004_bib0006","first-page":"581","article-title":"Antiemetics 36","author":"Anandabaskar","year":"2021","journal-title":"Abialbon Paul Nishanthi Anandabaskar Jayanthi Mathaiyan"},{"key":"10.1016\/j.htct.2022.02.004_bib0007","doi-asserted-by":"crossref","DOI":"10.2174\/0929867328666210708091134","article-title":"Synthesis and development of indole based 5-HT3 receptor antagonists as anti-emetic drugs in oncology: an update","author":"Rivera-Fonseca","year":"2021","journal-title":"Curr Med Chem"},{"issue":"1","key":"10.1016\/j.htct.2022.02.004_bib0008","first-page":"121","article-title":"Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy","volume":"88","author":"Mahrous","year":"2021","journal-title":"Cancer ChemotherPharmacol"},{"issue":"1","key":"10.1016\/j.htct.2022.02.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000621","volume":"5","author":"Zhou","year":"2020","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.htct.2022.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","article-title":"Netupitant\/Palonosetron: a review in chemotherapy-induced nausea and vomiting","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.htct.2022.02.004_bib0011","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11010-019-03677-7","article-title":"Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib","volume":"465","author":"Chmielinska","year":"2020","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.htct.2022.02.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103143","article-title":"Efficacy of intravenous NEPA, a fixed NK1\/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin-and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies","volume":"157","author":"Aapro","year":"2021","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"4","key":"10.1016\/j.htct.2022.02.004_bib0013","first-page":"1273","article-title":"Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer","volume":"26","author":"Bubalo","year":"2018","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.htct.2022.02.004_bib0014","article-title":"Addition of aprepitant improves acute emesis control in children and adolescents receiving induction chemotherapy for acute myeloid leukaemia: a randomised, open-label trial","author":"Sharma","year":"2020","journal-title":"BMJ Supportive Palliat Care"},{"issue":"22","key":"10.1016\/j.htct.2022.02.004_bib0015","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.htct.2022.02.004_bib0016","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s11999-010-1357-x","article-title":"Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce nausea and vomiting?","volume":"468","author":"DiIorio","year":"2010","journal-title":"Clin Orthop Related Res"},{"issue":"3","key":"10.1016\/j.htct.2022.02.004_bib0017","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/ped.13780","article-title":"Evaluation of aprepitant and fosaprepitant in pediatric patients","volume":"61","author":"Saito","year":"2019","journal-title":"Pediatr Int"},{"issue":"3","key":"10.1016\/j.htct.2022.02.004_bib0018","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"23","key":"10.1016\/j.htct.2022.02.004_bib0019","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.htct.2022.02.004_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1586\/14737140.4.5.715","article-title":"Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting","volume":"4","author":"Navari","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.htct.2022.02.004_bib0021","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/cncr.23364","article-title":"Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting","volume":"112","author":"Herrington","year":"2008","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.htct.2022.02.004_bib0022","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s00535-012-0746-1","article-title":"Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin","volume":"48","author":"Oyama","year":"2013","journal-title":"J Gastroenterol"},{"issue":"18_suppl","key":"10.1016\/j.htct.2022.02.004_bib0023","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1200\/jco.2007.25.18_suppl.9111","article-title":"Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy","volume":"25","author":"Grunberg","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2022.02.004_bib0024","first-page":"127","article-title":"Aprepitant and fosaprepitant use in children and adolescents at an academic medical center","volume":"19","author":"Shillingburg","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.htct.2022.02.004_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial","volume":"16","author":"Kang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.htct.2022.02.004_bib0026","article-title":"Use of aprepitant to prevent nausea and vomiting in children","volume":"21","author":"Buck","year":"2015","journal-title":"Pediatr Pharmacother"},{"issue":"6","key":"10.1016\/j.htct.2022.02.004_bib0027","first-page":"1111","article-title":"Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study","volume":"61","author":"Bodge","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.htct.2022.02.004_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial","volume":"16","author":"Kang","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.htct.2022.02.004_bib0029","first-page":"127","article-title":"Aprepitant and fosaprepitant use in children and adolescents at an academic medical center","volume":"19","author":"Shillingburg","year":"2014","journal-title":"Therapeutics"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:35:42Z","timestamp":1762868142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2531137922000414"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.02.004","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}